Abstract

This work presents an amplified colorimetric biosensor for circulating tumor DNA (ctDNA), which associates the hybridization chain reaction (HCR) amplification with G-Quadruplex DNAzymes activity through triplex DNA formation. In the presence of ctDNA, HCR occurs. The resulting HCR products are specially recognized by one sequence to include one GGG repeat and the other containing three GGG repeats, through the synergetic effect of triplex DNA and asymmetrically split G-Quadruplex forming. Such design takes advantage of the amplification property of HCR and the high peroxidase-like catalytic activity of asymmetrically split G-Quadruplex DNAzymes by means of triplex DNA formation, which produces color signals in the presence of ctDNA. Nevertheless, in the absence of ctDNA, no HCR happens. Thus, no triplex DNA and G-Quadruplex structure is formed, producing a negligible background. The colorimetric sensing platform is successfully applied in complex biological environments such as human blood plasma for ctDNA detection, with a detection limit corresponding to 0.1 pM. This study unambiguously uses triplex DNA forming as the pivot to integrate nucleic acid amplification and DNAzymes for producing a highly sensitive signal with low background.

Highlights

  • Circulating tumor DNA, composed of small fragments of nucleic acid, has been demonstrated to be a promising biomarker for classification, diagnosis, and prognosis of cancers, which attracts much attention to develop techniques for monitoring circulating tumor DNA (ctDNA) in blood[1,2,3]

  • The hybridization chain reaction (HCR) product with a strict duplex formation has an iterative 30-base homopyrimidine·homopurine druplex DNA region, which is specifially recognized by a third homopyrimidine or homopurine single-strand DNA by Hoogsteen or reverse Hoogsteen hydrogen resulting in the structure of triplex DNA

  • L2 has two functional parts, one part with 15-base homopyrimidine that can recognize homopyrimidine·homopurine druplex DNA of HCR product and form the triplex DNA, the other one to include the three-fourths of the G-quadruplex sequence[18]

Read more

Summary

Introduction

Circulating tumor DNA (ctDNA), composed of small fragments of nucleic acid, has been demonstrated to be a promising biomarker for classification, diagnosis, and prognosis of cancers, which attracts much attention to develop techniques for monitoring ctDNA in blood[1,2,3].

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call